American Heart Journal
Volume 156, Issue 6 , Pages 1147-1154 , December 2008

European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab—EUROTRANSFER Registry

  • Dariusz Dudek, MD, PhD, FESC

      Affiliations

    • Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland
    • Corresponding Author InformationReprint requests: Dariusz Dudek, MD, PhD, FESC, Department of Interventional Cardiology, Jagiellonian University Medical College, 17 Kopernika St., 31-501 Krakow, Poland.
    • ,
  • Zbigniew Siudak, MD

      Affiliations

    • Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland
    • ,
  • Magnus Janzon, MD, PhD

      Affiliations

    • Department of Cardiology, Linköping University Hospital, Linköping, Sweden
    • ,
  • Ralf Birkemeyer, MD

      Affiliations

    • Department of Cardiology, Schwarzwald-Baar Klinikum, Villingen-Schwenningen, Germany
    • ,
  • Guillermo Aldama-Lopez, MD

      Affiliations

    • Department of Cardiology, Hospital Juan Canalejo, Coruna, Spain
    • ,
  • Corrado Lettieri, MD

      Affiliations

    • Interventional Cardiology Department, Ospedale Carlo Poma, Mantova, Italy
    • ,
  • Bogdan Janus, MD

      Affiliations

    • Department of Interventional Cardiology, Specjalistyczny Szpital im. E. Szczeklika, Tarnow, Poland
    • ,
  • Andrzej Wisniewski, MD

      Affiliations

    • Department of Cardiology, Przemysl, Poland
    • ,
  • Sergio Berti, MD

      Affiliations

    • Department of Interventional Cardiology, Ospedale G. Pasquinucci, Massa, Italy
    • ,
  • Zoran Olivari, MD

      Affiliations

    • Ospedale S. Maria di Ca'Foncello, Treviso, Italy
    • ,
  • Tomasz Rakowski, MD, PhD

      Affiliations

    • Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland
    • ,
  • Lukasz Partyka, MD, PhD

      Affiliations

    • Department of Clinical Biochemistry, Jagiellonian University Medical College, Krakow, Poland
    • ,
  • Jochen Goedicke, MD

      Affiliations

    • Eli Lilly Critical Care Europe, Geneva, Switzerland
    • ,
  • Krzysztof Zmudka, MD, PhD

      Affiliations

    • Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland
    • ,
  • on behalf of EUROTRANSFER Registry investigators

Received 29 January 2008 ,Accepted 3 August 2008.

References 

  1. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators . Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006;367:569–578
  2. Antman EA, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2008;117:296–329
  3. Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008;358:2205–2217
  4. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2003;24:28–66
  5. Flynn MR, Barrett C, Cosio FG, et al. The Cardiology Audit and Registration Data Standards (CARDS), European data standards for clinical cardiology practice. Eur Heart J. 2005;26:308–313
  6. Antoniucci D, Valenti R, Migliorini A, et al. Relation of time to treatment and mortality in patients with acute myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol. 2002;89:1248–1252
  7. D'Agostino RB. Tutorial in Biostatistics—Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–2281
  8. Heer T, Zeymer U, Juenger C, et al. Beneficial effects of abciximab in patients with primary percutaneous intervention for acute ST segment elevation myocardial infarction in clinical practice. Heart. 2006;92:1484–1489
  9. Tornvall P, Nilsson T, Lagerqvist B. Effects on mortality of abciximab in ST-elevation myocardial infarction treated with percutaneous coronary intervention including stent implantation. J Intern Med. 2006;260:363–368
  10. Gersh BJ, Stone GW, White HD, et al. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future?. JAMA. 2005;293:979–986
  11. Steg PG, López-Sendón J, Lopez de Sa E, et al. External validity of clinical trials in acute myocardial infarction. Arch Intern Med. 2007;167:68–73

 ClinicalTrials.gov identifier: NCT00378391.

 Author disclosure statements can be found in Appendix A.

PII: S0002-8703(08)00661-3

doi: 10.1016/j.ahj.2008.08.004

American Heart Journal
Volume 156, Issue 6 , Pages 1147-1154 , December 2008

Article Tools

* Image Usage & Resolution